Nanobiotix (NASDAQ:NBTX) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Nanobiotix (NASDAQ:NBTX) in a research note issued to investors on Friday morning, Zacks.com reports.

Nanobiotix Stock Up 0.3 %

Shares of NBTX opened at $5.83 on Friday. The stock’s 50 day moving average is $6.26 and its two-hundred day moving average is $6.54. Nanobiotix has a twelve month low of $1.75 and a twelve month high of $11.00.

Institutional Trading of Nanobiotix

An institutional investor recently raised its position in Nanobiotix stock. Baillie Gifford & Co. increased its stake in shares of Nanobiotix S.A. (NASDAQ:NBTX) by 38.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,936,195 shares of the company’s stock after purchasing an additional 536,195 shares during the quarter. Baillie Gifford & Co. owned approximately 5.35% of Nanobiotix worth $16,942,000 as of its most recent filing with the Securities and Exchange Commission. 38.81% of the stock is owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.